

Surgical Science Q3 2024 - Sequential improvements continue

Redeye updates its estimates following Surgical Science's Q3 2024 report, which beat our expectations. Educational Products continued its sequential recovery, while solid Industry/OEM sales matched our projections. We expect a seasonally strong fourth quarter and solid growth in 2025e. We nudge up our estimates and valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Surgical Science Q3 2024 - Sequential improvements continue